Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

For patients with advanced basal cell carcinoma (BCC), including locally advanced or metastatic BCC not amenable to curative surgery or radiotherapy, hedgehog pathway inhibitors (HHI) vismodegib and sonidegib are approved as first-line systemic treatment. Results from clinical trials highlight that...

Descripción completa

Detalles Bibliográficos
Autores principales: Dessinioti, Clio, Stratigos, Alexander J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656142/
https://www.ncbi.nlm.nih.gov/pubmed/37992360
http://dx.doi.org/10.5826/dpc.1304a252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656142/
https://www.ncbi.nlm.nih.gov/pubmed/37992360
http://dx.doi.org/10.5826/dpc.1304a252

Ejemplares similares